查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2004998

猪疫苗市场：依疫苗类型、目标疾病、最终用户、给药途径、技术和剂型划分－2026-2032年全球市场预测

Porcine Vaccines Market by Vaccine Type, Disease Indication, End User, Route Of Administration, Technology, Dosage Form - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，猪疫苗市场价值将达到 19.4 亿美元，到 2026 年将成长到 20.7 亿美元，到 2032 年将达到 31.2 亿美元，复合年增长率为 6.99%。

主要市场统计数据
基准年 2025 19.4亿美元
预计年份：2026年 20.7亿美元
预测年份：2032年 31.2亿美元
复合年增长率 (%) 6.99%

一篇清晰权威的介绍，说明了近期科学、监管和运营方面的变化如何重新定义猪疫苗研发的优先事项。

猪隻疫苗领域正处于转型期，其驱动力来自于技术创新、生产方法的改进以及养殖场需求的转变。核酸技术的进步、佐剂配方的优化以及给药途径的改进，都改变了人们对产品性能的预期以及研发流程。同时，监管机构也正在更新新平台和生产品质框架的指导意见，这要求研发人员和生产商能够更灵活地调整其临床开发计画和生产控制措施。

平台创新、监测数据和以现场为中心的管理方法如何推动您的猪隻疫苗策略发生系统性转变？

随着平台技术和疾病标靶策略的日益成熟，猪隻免疫的前景正从渐进式产品改进转向结构性变革。基于RNA的疗法、重组表达系统和病毒载体，结合佐剂和製剂技术的进步，正在加速抗原发现并实现更灵活的生产。这些技术的整合缩短了从病原体鑑定到候选疫苗部署的时间，改变了企业规划产品线和分配研发资源的方式。

对 2025 年美国实施的关税变化对营运炼和采购的影响进行全面分析。

美国2025年宣布的关税政策调整对猪隻疫苗相关相关人员的采购、供应链经济和战略采购产生了多方面的影响。某些生技药品原料和部分生产耗材的关税上调，推高了依赖国际原料供应的供应商的投入成本，进而影响了製造商和合约服务供应商的定价策略和供应商选择。为此，许多机构审查了其供应商基础，并加快了对替代性国内或区域供应商的认证，以降低关税变化带来的风险。

将疫苗平台、目标疾病、最终用户需求、给药途径、製造技术和剂型与策略重点连结起来的综合細項分析。

一个精细的细分框架揭示了产品开发、部署策略和最终用户接受度如何因疫苗类型、适应症、最终用户、给药途径、技术和剂型而异。灭活疫苗、减毒活病毒疫苗、mRNA疫苗、次单位疫苗和病毒载体疫苗之间的差异会影响研发进度和监管考量。例如，灭活疫苗可进一步分为裂解病毒製剂、亚细胞製剂和全病毒製剂，而减毒活病毒疫苗则根据其异质设计和同质设计进行区分。 mRNA製剂需要根据其是否扩增或自扩增而进行不同的最佳化，而次单位疫苗则必须在多醣亚次单元策略和蛋白质次单元策略之间做出选择。病毒载体平台可以利用腺病毒或痘病毒载体骨架，每种载体在免疫学和生产方面都有不同的权衡取舍。

美洲、欧洲、中东和非洲以及亚太地区的区域策略挑战将决定猪疫苗的监管、分销和部署管道。

区域趋势对塑造研究重点、监管策略和商业化途径至关重要。美洲呈现出一个异质性生态系统，大规模商业运营和先进的兽医服务网络推动了对复杂平台解决方案和精准免疫策略的需求，而监管重点则放在生产品质和核准后监测上。相较之下，欧洲、中东和非洲的法规结构和基础设施差异显着，需要灵活的商业化模式，以适应高度监管的市场以及低温运输和兽医服务能力有限的地区。亚太地区由于特定区域创新技术的快速应用，以及中东和非洲小规模农业人口的广泛分布，需要采取类似的策略，在应用高科技平台的同时，兼顾成本效益高、适合田间实际情况的疫苗选择。

创新主导研发公司、契约製造和策略伙伴如何为猪疫苗的整个价值链创造竞争优势？

竞争格局呈现出多元化的特点，既有成熟的动物用药品公司，也有专注于生物技术创新的企业、合约契约製造机构（CDMO）和学术研究中心。领先的研发公司正优先考虑平台多元化，以平衡短期商业产品和长期临床实验候选药物，并经常寻求能够将临床开发优势与可扩展生产技术相结合的伙伴关係关係。契约製造製造商和CDMO的角色日益重要，它们使中小创新企业能够利用符合GMP标准的生产系统，并使大型企业能够在避免固定资产过度投资的同时，柔软性管理其生产能力。

为开发人员和相关人员提供极具影响力和可操作性的策略建议，以加速猪疫苗领域的平台准备、供应弹性和最终用户采用。

产业领导者应采取三支柱策略方针，将科学知识与业务永续营运和精简的市场准入相结合。首先，优先投资兼具弹性和广度的平台。例如，在维持优化传统产品线的同时，扩展RNA和重组技术能力，既能快速应对新出现的威胁，又能稳定地提供针对地方性疾病的产品。其次，透过认证取代原料、投资区域生产或填充和包装能力，以及加强低温运输基础设施，建构供应链韧性，从而降低因贸易中断和关税导致的成本转移而带来的风险。

严谨的多面向调查方法，包括与专家的初步访谈、监管审查、科学文献整合以及基于情境的供应链分析。

本研究整合了从科学文献、监管指导文件、行业资讯披露、技术简报以及与价值链各环节专家的访谈中获得的定性和定量资讯。研究优先考虑了平台免疫学和药物科学的同行评审研究、与生技药品和新型疗法相关的监管指南以及来自生产和分销相关人员的营运文件，从而全面观点了技术、供应和应用趋势。

结论强调整合是未来猪隻疫苗接种发展的基础，重点在于技术融合、供应弹性和协作方法。

猪疫苗生态系统正日益受到技术创新、务实考量和不断变化的政策环境三者相互作用的影响。平台技术的进步为扩大预防范围和提高反应速度提供了切实机会，但要实现这些优势，需要对生产柔软性、监管策略和现场供给能力进行协调一致的投资。同时，贸易政策的变化和供应链压力凸显了区域多元化和供应商合格对于确保供应连续性和控製成本风险的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：猪疫苗市场：依疫苗类型划分

  • 失活
    • 分裂病毒
    • 细胞内成分
    • 所有病毒
  • 减毒活病毒疫苗
    • 不同物种
    • 同种
  • mRNA
    • 未扩增的mRNA
    • 自扩增mRNA
  • 次单元
    • 多醣体次单元
    • 蛋白质次单元
  • 病毒载体类型
    • 腺病毒载体
    • 痘病毒载体

第九章：猪疫苗市场：依目标疾病划分

  • 经典猪瘟
  • 猪丹毒
  • 猪繁殖与呼吸综合症
  • 猪流感

第十章：猪疫苗市场：依最终用户划分

  • 商业农场
  • 研究机构
  • 小农户
  • 动物医院

第十一章：猪隻疫苗市场：依给药途径划分

  • 皮内注射
  • 肌肉内部
  • 鼻内
  • 口服
  • 皮下

第十二章：猪疫苗市场：依技术划分

  • 传统的
    • 减毒活病毒疫苗
    • 灭活全抗原
  • DNA
  • 重组
    • 细菌表达
    • 昆虫细胞表达
    • 酵母表达
  • RNA
  • VLP

第十三章：猪疫苗市场：以剂型划分

  • 乳液
  • 液体
  • 冷冻干燥

第十四章：猪疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：猪疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 猪疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国猪疫苗市场

第十八章：中国猪疫苗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bimeda Holdings PLC
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Chengdu Tianbang Biological Products Co., Ltd.
  • Chopper Animal Health Co., Ltd.
  • Elanco Animal Health Incorporated
  • Hipra, SA
  • Indian Immunologicals Ltd.
  • Jinyu Bio-Technology Co., Ltd.
  • Kyoritsu Seiyaku Corporation
  • Merck & Co., Inc.
  • Pharmgate Animal Health, LLC
  • Phibro Animal Health Corporation
  • Qilu Animal Health Products Co., Ltd.
  • Vaxxinova International BV
  • Venkateshwara Hatcheries Pvt. Ltd.
  • Zoetis Inc.
Product Code: MRR-742BD5183CF6

The Porcine Vaccines Market was valued at USD 1.94 billion in 2025 and is projected to grow to USD 2.07 billion in 2026, with a CAGR of 6.99%, reaching USD 3.12 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.94 billion
Estimated Year [2026] USD 2.07 billion
Forecast Year [2032] USD 3.12 billion
CAGR (%) 6.99%

A clear, authoritative primer explaining how recent scientific, regulatory, and operational changes are redefining priorities in porcine vaccine development

The porcine vaccine arena stands at an inflection point driven by converging scientific innovation, evolving production modalities, and shifting farm-level needs. Advances in nucleic acid technologies, improved adjuvant formulations, and more refined delivery routes have altered both product performance expectations and development pathways. Meanwhile, regulatory authorities are updating guidance on novel platforms and manufacturing quality frameworks, which requires developers and producers to adapt clinical development plans and manufacturing controls with greater agility.

Operational pressures across supply chains and the increasing focus on biosafety and traceability are reshaping procurement practices among commercial farms, veterinary hospitals, and research institutes. As stakeholders prioritize resilience and predictability, there is a growing premium on vaccines that combine robust efficacy profiles with simplified administration and storage requirements. Collectively, these dynamics are redefining investment priorities, strategic partnerships, and pipeline development across the sector.

How converging platform innovations, surveillance intelligence, and field-centric delivery approaches are driving systemic transformation in porcine vaccine strategies

The landscape for porcine immunization is moving from incremental product improvement toward structural transformation as platform technologies and disease targeting strategies mature. RNA-based modalities, recombinant expression systems, and viral vectors are converging with improved adjuvant and formulation science to enable faster antigen discovery and adaptable manufacturing. This technological convergence shortens the interval between pathogen identification and candidate deployment, thereby changing how companies plan pipelines and allocate R&D resources.

Concurrently, disease surveillance networks and data integration across farms and veterinary services are enabling earlier outbreak detection and more precise vaccine deployment strategies. These capabilities are encouraging stakeholders to invest in modular production capacity, cold chain innovations, and alternative routes of administration that reduce labor and stress at the herd level. As a result, strategic emphasis is shifting toward platform flexibility, cross-protection potential, and ease of field use, which together are driving new collaboration models between developers, contract manufacturers, and end users.

Comprehensive analysis of the cascading operational and sourcing consequences that resulted from the United States tariff changes implemented in 2025

US tariff policy changes announced in 2025 have had multifaceted implications across sourcing, supply chain economics, and strategic procurement for porcine vaccine stakeholders. Increased duties on selected biologics inputs and certain manufacturing consumables elevated input costs for suppliers that rely on international raw material flows, which in turn influenced pricing strategies and vendor selection for manufacturers and contract service providers. In response, many organizations reassessed supplier footprints and accelerated qualification of alternative domestic or regional suppliers to reduce exposure to tariff variability.

These adjustments also pushed manufacturers to evaluate inventory policies and to strengthen contractual terms with upstream suppliers to secure supply continuity. For end users such as commercial farms and veterinary networks, procurement practices evolved toward longer-term purchasing agreements and collaborative planning to smooth supply disruptions. Policymakers and industry groups engaged in dialogue to clarify tariff scope and to explore mitigations, including targeted exemptions, streamlined customs processes, and incentives for local production capacity to reinforce resilience and hedging against future trade volatility.

An integrated segmentation analysis linking vaccine platforms, disease targets, end-user needs, administration routes, production technologies, and dosage formats to strategic priorities

A nuanced segmentation framework reveals how product development, deployment strategies, and end-user uptake diverge across vaccine type, disease indication, end user, route of administration, technology, and dosage form. Vaccine type distinctions between Inactivated formats, Live Attenuated preparations, mRNA constructs, Subunit vaccines, and Virus Vectored solutions shape development timelines and regulatory considerations; for example, Inactivated vaccines vary further as Split Virus, Subcellular, and Whole Virus formulations, while Live Attenuated approaches are differentiated by Heterologous and Homologous design choices. mRNA modalities require different optimization depending on whether they are Non-Amplifying or Self-Amplifying constructs, and Subunit vaccines call for choices between Polysaccharide Subunit and Protein Subunit strategies. Virus Vectored platforms may leverage Adenovirus Vector or Poxvirus Vector backbones, each with distinct immunologic and manufacturing trade-offs.

Disease indication segmentation including Classical Swine Fever, Erysipelas, Porcine Reproductive And Respiratory Syndrome, and Swine Influenza directs antigen selection priorities and field trial design. End users such as Commercial Farms, Research Institutes, Smallholder Farms, and Veterinary Hospitals present contrasting adoption criteria that influence dosing regimens, packaging, and service models. Route of administration choices spanning Intradermal, Intramuscular, Intranasal, Oral, and Subcutaneous determine product format and on-farm labor implications. Underlying technology categories of Conventional, DNA, Recombinant, RNA, and VLP further shape development pathways, with Conventional pathways subdividing into Attenuated Live and Killed Whole approaches and Recombinant strategies differentiating between Bacteria Expressed, Insect Cell Expressed, and Yeast Expressed production methods. Dosage form variants across Emulsion, Liquid, and Lyophilized formats affect logistics and shelf-life considerations. Taken together, this segmentation matrix clarifies where technical investment and commercialization focus will yield the greatest operational and clinical impact.

Regional strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine regulatory, distribution, and adoption pathways for porcine vaccines

Regional dynamics are critical for shaping research priorities, regulatory strategy, and commercialization approaches. The Americas present a heterogeneous ecosystem in which large commercial operations and sophisticated veterinary service networks drive demand for advanced platform solutions and precision immunization strategies, while regulatory scrutiny emphasizes manufacturing quality and post-licensure surveillance. In contrast, Europe, Middle East & Africa exhibits wide variability across regulatory frameworks and infrastructure, requiring adaptable commercialization models that can accommodate both highly regulated markets and areas with more constrained cold chain or veterinary services capacity. Asia-Pacific combines rapid innovation adoption in certain hubs with extensive smallholder populations in other geographies, necessitating a dual-track approach that balances high-tech platform deployment alongside cost-effective, field-friendly vaccine options.

These regional contrasts influence R&D prioritization, partnership models, and distribution strategies. For developers and suppliers, success depends on tailoring dossiers and evidence packages to regulatory expectations in each region while designing logistics and service models that match local end-user capabilities. Consequently, strategic regional investments in manufacturing, cold chain enhancements, and localized training programs can materially affect uptake and long-term adoption trajectories across geographies.

How innovation-led developers, contract manufacturers, and strategic collaborations are shaping competitive differentiation across the porcine vaccine value chain

The competitive landscape is characterized by a mix of established animal health corporations, specialized biotech innovators, contract manufacturing organizations, and academic research centers. Leading developers emphasize platform diversification to balance near-term commercial products with longer-term investigational candidates, often pursuing partnerships that combine clinical development strength with scalable manufacturing expertise. Contract manufacturers and CDMOs are playing an increasingly pivotal role, enabling smaller innovators to access GMP-compliant production and allowing larger firms to manage capacity flexibility without over-investing in fixed assets.

Strategic behaviors among companies include vertical integration of supply chains, targeted acquisitions to close capability gaps in novel platforms, and collaborative research agreements that accelerate antigen discovery and immunogenicity testing. Firms that invest in robust regulatory affairs teams and post-approval surveillance capabilities achieve smoother product rollouts and stronger stakeholder trust. Meanwhile, companies prioritizing field-centric design-such as simplified dosing regimens, thermostable formulations, and minimally invasive delivery-are better positioned to capture adoption among diverse end users. Overall, sustained competitive advantage arises from the intersection of scientific excellence, manufacturing resilience, and deep understanding of end-user operational needs.

High-impact, practical strategic recommendations for developers and stakeholders to accelerate platform readiness, supply resilience, and end-user adoption in the porcine vaccine sector

Industry leaders should adopt a three-pronged strategic approach that aligns scientific capability with operational resilience and market access facilitation. First, prioritize platform investments that deliver both agility and breadth; for example, expanding RNA and recombinant capabilities while maintaining optimized conventional pipelines can enable both rapid response to emergent threats and stable product offerings for endemic diseases. Second, build supply chain resilience by qualifying alternative raw material sources, investing in regional production or fill-finish capacity, and enhancing cold chain infrastructure to reduce vulnerability to trade disruptions and tariff-induced cost shifts.

Third, strengthen end-user engagement by co-developing administration and training programs with veterinary networks and farm groups so that product attributes are matched to field realities. In parallel, pursue regulatory engagement early in development to align on evidence requirements for novel platforms and to expedite approval pathways. Finally, consider flexible commercial models such as subscription-style supply agreements or tiered pricing to expand reach across different end-user segments while maintaining sustainable revenue streams. These combined actions will help organizations convert scientific advances into reliable, accessible immunization solutions.

A rigorous, multi-source research methodology integrating primary expert interviews, regulatory review, scientific literature synthesis, and scenario-based supply chain analysis

This research synthesized qualitative and quantitative inputs across scientific literature, regulatory guidance documents, industry disclosures, technical briefings, and interviews with subject-matter experts across the value chain. Evidence synthesis prioritized peer-reviewed studies on platform immunology and formulation science, regulatory guidelines relevant to biologicals and novel modalities, and operational documentation from manufacturing and distribution stakeholders to create a comprehensive perspective on technology, supply, and adoption trends.

In addition to secondary research, primary engagements included structured interviews with laboratory researchers, manufacturing leaders, regulatory affairs professionals, and farm-level practitioners to validate assumptions and surface practical adoption barriers. Triangulation techniques were used to reconcile differing viewpoints and to ensure that conclusions reflect both scientific plausibility and operational feasibility. Analytic methods emphasized thematic coding for qualitative inputs and scenario analysis for supply chain and policy impact assessment, thereby providing robust, actionable insights for decision-makers.

Concluding synthesis emphasizing technology convergence, supply resilience, and collaborative approaches as the foundations for future progress in porcine immunization

The porcine vaccine ecosystem is increasingly defined by the interplay of technological innovation, operational pragmatism, and evolving policy environments. Advances in platform technologies offer genuine opportunities to improve protection breadth and speed of response, but realizing those gains requires synchronized investment in manufacturing flexibility, regulatory strategy, and field delivery capabilities. In parallel, trade policy shifts and supply chain pressure underscore the importance of regional diversification and supplier qualification to protect continuity of supply and to manage cost exposure.

Going forward, stakeholders that combine platform agility with deep end-user engagement and resilient supply arrangements will be best positioned to convert scientific progress into measurable animal health outcomes. Cross-sector collaboration-spanning developers, service providers, regulators, and farm networks-will remain essential to accelerate responsible adoption and to ensure that innovations translate into sustainable improvements in disease control and farm productivity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Porcine Vaccines Market, by Vaccine Type

  • 8.1. Inactivated
    • 8.1.1. Split Virus
    • 8.1.2. Subcellular
    • 8.1.3. Whole Virus
  • 8.2. Live Attenuated
    • 8.2.1. Heterologous
    • 8.2.2. Homologous
  • 8.3. MRNA
    • 8.3.1. Non Amplifying MRNA
    • 8.3.2. Self Amplifying MRNA
  • 8.4. Subunit
    • 8.4.1. Polysaccharide Subunit
    • 8.4.2. Protein Subunit
  • 8.5. Virus Vectored
    • 8.5.1. Adenovirus Vector
    • 8.5.2. Poxvirus Vector

9. Porcine Vaccines Market, by Disease Indication

  • 9.1. Classical Swine Fever
  • 9.2. Erysipelas
  • 9.3. Porcine Reproductive And Respiratory Syndrome
  • 9.4. Swine Influenza

10. Porcine Vaccines Market, by End User

  • 10.1. Commercial Farm
  • 10.2. Research Institute
  • 10.3. Smallholder Farm
  • 10.4. Veterinary Hospital

11. Porcine Vaccines Market, by Route Of Administration

  • 11.1. Intradermal
  • 11.2. Intramuscular
  • 11.3. Intranasal
  • 11.4. Oral
  • 11.5. Subcutaneous

12. Porcine Vaccines Market, by Technology

  • 12.1. Conventional
    • 12.1.1. Attenuated Live
    • 12.1.2. Killed Whole
  • 12.2. DNA
  • 12.3. Recombinant
    • 12.3.1. Bacteria Expressed
    • 12.3.2. Insect Cell Expressed
    • 12.3.3. Yeast Expressed
  • 12.4. RNA
  • 12.5. VLP

13. Porcine Vaccines Market, by Dosage Form

  • 13.1. Emulsion
  • 13.2. Liquid
  • 13.3. Lyophilized

14. Porcine Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Porcine Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Porcine Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Porcine Vaccines Market

18. China Porcine Vaccines Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Bimeda Holdings PLC
  • 19.6. Boehringer Ingelheim International GmbH
  • 19.7. Ceva Sante Animale S.A.
  • 19.8. Chengdu Tianbang Biological Products Co., Ltd.
  • 19.9. Chopper Animal Health Co., Ltd.
  • 19.10. Elanco Animal Health Incorporated
  • 19.11. Hipra, S.A.
  • 19.12. Indian Immunologicals Ltd.
  • 19.13. Jinyu Bio-Technology Co., Ltd.
  • 19.14. Kyoritsu Seiyaku Corporation
  • 19.15. Merck & Co., Inc.
  • 19.16. Pharmgate Animal Health, LLC
  • 19.17. Phibro Animal Health Corporation
  • 19.18. Qilu Animal Health Products Co., Ltd.
  • 19.19. Vaxxinova International BV
  • 19.20. Venkateshwara Hatcheries Pvt. Ltd.
  • 19.21. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PORCINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PORCINE VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PORCINE VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PORCINE VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PORCINE VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES PORCINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA PORCINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PORCINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PORCINE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS PORCINE VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL PORCINE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 269. GCC PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. GCC PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. GCC PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 272. GCC PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 273. GCC PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 274. GCC PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 275. GCC PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 276. GCC PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 277. GCC PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. GCC PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. GCC PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. GCC PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 281. GCC PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 282. GCC PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 311. G7 PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 312. G7 PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. G7 PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 314. G7 PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 315. G7 PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 316. G7 PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 317. G7 PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 318. G7 PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 319. G7 PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 320. G7 PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 321. G7 PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. G7 PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 323. G7 PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 324. G7 PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 325. NATO PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 326. NATO PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. NATO PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 328. NATO PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 329. NATO PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 330. NATO PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 331. NATO PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2032 (USD MILLION)
  • TABLE 332. NATO PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 333. NATO PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. NATO PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. NATO PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 336. NATO PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 337. NATO PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 338. NATO PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 339. GLOBAL PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 340. UNITED STATES PORCINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 341. UNITED STATES PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. UNITED STATES PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 343. UNITED STATES PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 344. UNITED STATES PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 345. UNITED STATES PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 346. UNITED STATES PORCINE VACCINES MARKET SIZE,